Proceedings of the Health Science International Conference (HSIC 2017) 2017
DOI: 10.2991/hsic-17.2017.62
|View full text |Cite
|
Sign up to set email alerts
|

Indicaxanthin, Miraxanthin-V, and Hexahydrocurcumin as Potential Erythropoietin Agonist in Silico to Treat Anemia in Chronic Kidney Disease

Abstract: Background: Anemia is the most frequent complication of Chronic Kidney Disease (CKD) which is

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2
1

Relationship

3
0

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…Indicaxanthin play a role as an erythropoietin agonist which will increase the expression of matriptase-2. Miraxanthin V and Boeravinone F can neutralize hepcidin and inhibit hepcidin-ferroportin binding [4][5][6]. In silico, M. jalapa has also been developed for cancer and stroke therapy [7,8].…”
Section: Introductionmentioning
confidence: 99%
“…Indicaxanthin play a role as an erythropoietin agonist which will increase the expression of matriptase-2. Miraxanthin V and Boeravinone F can neutralize hepcidin and inhibit hepcidin-ferroportin binding [4][5][6]. In silico, M. jalapa has also been developed for cancer and stroke therapy [7,8].…”
Section: Introductionmentioning
confidence: 99%
“…In previous study, we found several phytochemicals in silico using molecular docking approach that play a role in iron metabolism. Indicaxanthin, Miraxanthin, and Boeravinone F, the member of Betaxanthin group found in Mirabilis jalapa have potentially developed as antagonist hepcidin and erythropoietin agonist [8][9][10].…”
Section: Introductionmentioning
confidence: 99%